Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Senti Biosciences HoldingsSNTI -2.57%18 Net-Net Working Capital is $-0.96 as of Jun. 2026. GuruFocus rates SNTI with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 834 Biotechnology companies, Senti Biosciences Holdings ranks worse than 119903.96% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Senti Biosciences Holdings's Net-Net Working Capital for the quarter that ended in Jun. 2026 was $-0.96.
The industry rank for Senti Biosciences Holdings's Net-Net Working Capital or its related term are showing as below:
SNTI's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 5.455 * Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.
Senti Biosciences Holdings (NAS:SNTI) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Senti Biosciences Holdings Net-Net Working Capital Related Terms
Senti Biosciences Holdings Net-Net Working Capital Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senti Biosciences Holdings Net-Net Working Capital Chart
SNTI vs ZEOX, BCDA, COCP: Net-Net Working Capital Comparison
For the Biotechnology subindustry, Senti Biosciences Holdings's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senti Biosciences Holdings Price-to-Net-Net-Working-Capital vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Senti Biosciences Holdings's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Senti Biosciences Holdings's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $-0.96 mean?
Senti Biosciences Holdings (SNTI) has a Net-Net Working Capital of $-0.96 as of Jun. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Senti Biosciences Holdings According to the industry distribution chart, Senti Biosciences Holdings ranks #999999 out of 834 companies in the Biotechnology industry.
Is Senti Biosciences Holdings' Net-Net Working Capital too high?
Senti Biosciences Holdings' current Net-Net Working Capital is $-0.96. Based on the distribution chart, Senti Biosciences Holdings ranks #999999 out of 834 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Senti Biosciences Holdings has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Senti Biosciences Holdings' Net-Net Working Capital compare to ZEOX and BCDA?
According to the Biotechnology industry distribution chart, Senti Biosciences Holdings ranks #999999 out of 834 companies for Net-Net Working Capital. This places Senti Biosciences Holdings in the lower half of its industry. The industry median Net-Net Working Capital is 5.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Biotechnology company?
The median Net-Net Working Capital among Biotechnology companies is 5.46, based on 834 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Senti Biosciences Holdings For the Biotechnology industry, the median Net-Net Working Capital is 5.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senti Biosciences Holdings's current Net-Net Working Capital is $-0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senti Biosciences Holdings stock overvalued right now?
Senti Biosciences Holdings (SNTI) has a current Net-Net Working Capital of $-0.96. The current Net-Net Working Capital is $-0.96. Senti Biosciences Holdings' overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Senti Biosciences Holdings (SNTI), the current Net-Net Working Capital is $-0.96 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
18GF Score
Get the complete analysis for SNTI
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNTI has been successfully added to your 
